Policy & News
2023-06-25
Circular of the Drug Review Centre of the State Drug Administration on the Publication of the Technical Guidelines for Clinical Trials of Human-Derived Stem Cells and Their Derived Cellular Therapeutic Products (for Trial Implementation) (No. 37 of 2023)
View More
2023-06-05
The Implementing Rules of the Regulations on Human Genetic Resources Management have been considered and adopted at the 3rd Ministerial Meeting of the Ministry of Science and Technology on 11 May 2023, and are hereby promulgated and shall come into force on 1 July 2023.
View More
Management of Adverse Drug Reaction Reporting and Monitoring
2023-04-27
Article 1 In order to strengthen the post-market supervision of medicines, standardise the reporting and monitoring of adverse drug reactions, control the risks of medicines in a timely and effective manner, and safeguard the safety of medicines for the public, these Measures are formulated on the basis of the Drug Administration Law of the People's Republic of China and other relevant laws and regulations.
View More
Drug Manufacturing Supervision and Administration Measures
2023-04-27
The Measures for the Supervision and Administration of Pharmaceutical Production was considered and adopted at the 1st Bureau Meeting of 2020 of the State Administration of Market Supervision and Administration on 15 January 2020, and is hereby promulgated and shall come into force from 1 July 2020 onwards.
View More
2023-04-27
Article 1 This Law is enacted for the purpose of strengthening vaccine management, ensuring the quality and supply of vaccines, regulating preventive vaccination, promoting the development of the vaccine industry, safeguarding public health and maintaining public health safety.
View More
